HCV virology and diagnosis

Roger, Steven; Ducancelle, Alexandra; Guillou‐Guillemette, Hélène Le; Gaudy, Catherine; Lunel, F.

doi:10.1016/j.clinre.2021.101626

Cited by 43 publications

(24 citation statements)

References 110 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatitis C virus (HCV) infection is a major cause of severe liver diseases, including chronic hepatitis, cirrhosis, and hepatocellular carcinoma. According to the World Health Organization ( WHO, 2017 ), approximately 71 million people worldwide are infected with HCV, and at least 400,000 people die annually from HCV-related liver disease ( WHO, 2017 ; Spearman et al., 2019 ; Roger et al., 2021 ). HCV transmission primarily occurs through accidental needle sticks in medical settings, using injectable drugs, and receiving a blood transfusion before 1992, which was when blood screening became routine ( Pietschmann and Brown, 2019 ; Hollande et al., 2020 ).…”

Section: Introductionmentioning

confidence: 99%

“…Acute HCV cases account for about 15–20% of total cases, and post-acute HCV-infected patients have a 50–80% chance of developing a chronic infection ( Narayanamurthy et al., 2021 ). If untreated, patients have a 20% risk of developing cirrhosis, of whom a small percentage may also develop hepatocellular carcinoma ( Roger et al., 2021 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick

Wang

Zhang

Zhou

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is a global public health threat. Reaching the World Health Organization’s objective for eliminating viral hepatitis by 2030 will require a precise disease diagnosis. While immunoassays and qPCR play a significant role in detecting HCV, rapid and accurate point-of-care testing is important for pathogen identification. This study establishes a reverse transcription recombinase-aided amplification–lateral flow dipstick (RT-RAA-LFD) assay to detect HCV. The intact workflow was completed within 30 min, and the detection limit for synthesized C/E1 plasmid gene-containing plasmid was 10 copies/μl. In addition, the test showed good specificity, with no cross-reactivity observed for hepatitis A virus, hepatitis B virus, HIV, syphilis, and human papillomavirus virus. Using extracted RNAs from 46 anti-HCV antibody-positive samples, RT-RAA-LFD showed 100% positive and negative concordance rates with qPCR. In summary, the RT-RAA-LFD assay established in this study is suitable for the rapid clinical detection of HCV at the community level and in remote areas.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick

Wang

Zhang

Zhou

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…HCV displays high genetic diversity as a result of defects in the repair activity of RNA-dependent RNA polymerase and the absence of 5′-to-3′ exonuclease activity ( 3 ). Based on phylogenetic analysis of the genome sequence, HCV is now classified into eight genotypes (GTs) and 91 subtypes ( 4 , 5 ).…”

Section: Introductionmentioning

confidence: 99%

Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China

et al. 2021

View full text Add to dashboard Cite

show abstract

“…As one of the major causes of liver-related morbidity and mortality, including liver cirrhosis and hepatocellular carcinoma (HCC), chronic HCV infection is becoming an important public health burden, with around 71 million infections worldwide and at least 400,000 deaths per year (3)(4)(5). Currently, there is still no effective vaccine for the prevention of HCV infection (6).…”

Section: Introductionmentioning

confidence: 99%

Achieving WHO target of HCV control in Hong Kong: challenges and strategies

Wang

Cheng

Lau

2021

GHM

View full text Add to dashboard Cite

With the introduction of effective directly acting antiviral agents (DAAs) therapy, control and elimination of hepatitis C virus (HCV) infection is becoming a feasible goal. In Hong Kong, HCV prevalence in general population is 0.3%-0.5% over the past decades. However, like other high-income areas/countries, high prevalence of HCV infection has been found in several population groups, such as people who inject drugs (PWID), patients undergoing dialysis, and human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/ AIDS) patients. Based on the epidemiological study using data retrieved from the Hong Kong HCV Registry from January 2005 to March 2017, the estimated territory-wide diagnosis rate and treatment rate of HCV infection were only 50.9% and 12.4%, respectively. Although these rates was comparable to many developed countries/areas, the performances remained substantially below 90% and 80%, the 2030 targets proposed by World Health Organization (WHO). In recognition of the challenges, the Hong Kong Government set up the Steering Committee on Prevention and Control of Viral Hepatitis (SCVH) which formulated the Hong Kong Viral Hepatitis Action Plan 2020-2024. The Action Plan adopts four key strategies, as described in the WHO framework for global action, namely, awareness, surveillance, prevention and treatment. With the effective implementation of the Action Plan, especially in targeted screening of high-risk populations and more generalized use of the highly efficacious DAAs for all diagnosed HCV subjects, the goals of reducing HCV transmission and HCV-related morbidity and mortality can be achieved in Hong Kong by 2030.

show abstract

HCV virology and diagnosis

Cited by 43 publications

References 110 publications

Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick

Rapid Visual Detection of Hepatitis C Virus Using Reverse Transcription Recombinase-Aided Amplification–Lateral Flow Dipstick

Characterization of a Novel Hepatitis C Subtype, 6xj, and Its Consequences for Direct-Acting Antiviral Treatment in Yunnan, China

Achieving WHO target of HCV control in Hong Kong: challenges and strategies

Contact Info

Product

Resources

About